TAT
Tyrosine aminotransferase
Also known as: ATTY_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P17735
- Gene
- TAT
- Ensembl
- ENSG00000198650
- Chromosome
- 16
- Canonical length
- 454 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This nuclear gene encodes a mitochondrial protein tyrosine aminotransferase which is present in the liver and catalyzes the conversion of L-tyrosine into p-hydroxyphenylpyruvate. Mutations in this gene cause tyrosinemia (type II, Richner-Hanhart syndrome), a disorder accompanied by major skin and corneal lesions, with possible cognitive disability. A regulator gene for tyrosine aminotransferase is X-linked. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
454 residues, UniProt reviewed canonical sequence.
>P17735|TAT
1 MDPYMIQMSS KGNLPSILDV HVNVGGRSSV PGKMKGRKAR WSVRPSDMAK KTFNPIRAIV
61 DNMKVKPNPN KTMISLSIGD PTVFGNLPTD PEVTQAMKDA LDSGKYNGYA PSIGFLSSRE
121 EIASYYHCPE APLEAKDVIL TSGCSQAIDL CLAVLANPGQ NILVPRPGFS LYKTLAESMG
181 IEVKLYNLLP EKSWEIDLKQ LEYLIDEKTA CLIVNNPSNP CGSVFSKRHL QKILAVAARQ
241 CVPILADEIY GDMVFSDCKY EPLATLSTDV PILSCGGLAK RWLVPGWRLG WILIHDRRDI
301 FGNEIRDGLV KLSQRILGPC TIVQGALKSI LCRTPGEFYH NTLSFLKSNA DLCYGALAAI
361 PGLRPVRPSG AMYLMVGIEM EHFPEFENDV EFTERLVAEQ SVHCLPATCF EYPNFIRVVI
421 TVPEVMMLEA CSRIQEFCEQ HYHCAEGSQE ECDKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TAT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 1,188 nTPM
Expression across tissuesHPA
Tissue
- liver: 1,188 nTPM
- breast: 55 nTPM
- testis: 1.7 nTPM
- gallbladder: 0.7 nTPM
- spleen: 0.7 nTPM
- retina: 0.6 nTPM
Single-cell type
- hepatocytes: 5,253 nCPM
- breast hormone-responsive cells: 171 nCPM
- cholangiocytes: 64 nCPM
- hepatic stellate cells: 19 nCPM
- kupffer cells: 13 nCPM
- enterocytes: 7 nCPM
Immune cell
- plasmacytoid DC: 0.6 nTPM
- naive B-cell: 0.4 nTPM
- basophil: 0.3 nTPM
- memory B-cell: 0.2 nTPM
- neutrophil: 0.2 nTPM
- memory CD4 T-cell: 0.1 nTPM
Brain region
- white matter: 1.5 nTPM
- cerebral cortex: 1.3 nTPM
- basal ganglia: 1.2 nTPM
- hypothalamus: 1.2 nTPM
- medulla oblongata: 1.2 nTPM
- pons: 1.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TAT.
Disease | AllUniProt
Conditions TAT is implicated in, by any mechanism.
- Tyrosinemia 2 (TYRSN2) MIM:276600
Disease | GeneticClinVar
67 pathogenic / likely-pathogenic of 474 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Tyrosinemia type II
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.61
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 0.76
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- 2-oxoglutarate metabolic process
- cellular response to insulin stimulus
- cellular response to retinoic acid
- glutamate metabolic process
- L-phenylalanine catabolic process
- L-tyrosine catabolic process
- liver regeneration
- response to cAMP
- response to cortisol
- response to dexamethasone
- response to ethanol
- response to mercury ion
- response to oxidative stress
Molecular functions
- amino acid binding
- identical protein binding
- pyridoxal phosphate binding
- L-tyrosine-2-oxoglutarate transaminase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Aminotransferases, class-I, pyridoxal-phosphate-binding site
- Aminotransferase, class I/classII, large domain
- Pyridoxal phosphate-dependent transferase, major domain
- Pyridoxal phosphate-dependent transferase, small domain
- Pyridoxal phosphate-dependent transferase
- Aminotransferase class I and II
- Tyrosine aminotransferase
- Tyrosine/nicotianamine aminotransferase
- Tyrosine aminotransferase ubiquitination region
- Aminotransferase ubiquitination site
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TAT in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TAT as an antibody target. Whether an autoantibody or antibody against TAT could matter depends on whether native TAT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TAT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TAT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...